[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Louisville\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,44,66,86,105,132,158,178,198,216,240,261,288,310,332,372,391,411,440,462,488,513,537,559,581],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645066",false,"NCT07678567","Pomegranate Dietary Supplements in AUD and ALD","Supplementation of Pomegranate Dietary Supplements and Characterization of Urolithin Metabotypes in Patients With Alcohol Use Disorder (AUD) and Alcohol-associated Liver Disease (ALD)","Healthy Group:\n\nInclusion: Healthy individuals, Exclusion: AUD, ALD, AC, and inflammatory conditions,\n\nAlcohol Use Disorder Group:\n\nInclusion: AUD diagnosis Exclusion: alcohol-associated systemic conditions\n\nAlcohol-associated liver disease Group:\n\nInclusion: early-stage ALD comorbid with AUD Exclusion: Only AUD or AUD with AC\n\nAlcohol-associated cirrhosis Inclusion: AC with AUD Exclusion: AUD, and early stage ALD, as well as determined by the study cohort criteria",true,"ALL","18 Years",{"count":20,"type":21},144,"ESTIMATED","OBSERVATIONAL","The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements. Recent publications have reported that urolithins are the major active metabolites responsible for the beneficial effects of eating pomegranates, berries, or walnuts. However, the production of urolithins from the parent compound ellagic acid (EA) is dependent upon the presence of certain bacteria in the human gut. In this trial, we propose to investigate variations in gut microbiota and their capacity to metabolize pomegranate dietary supplements (PDS) into active urolithins. We will measure the levels of urolithins in blood as well as inflammatory cytokines in plasma samples upon consumption of PDS.",[25,26,27,28],"Alcohol Use Disorder","Alcohol-associated Liver Disease","Alcoholic Cirrhosis","Healthy",[30],"Pomeragranate, AUD, ALD","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":21},"2027-01-01",{"date":39,"type":21},"2032-12-31",{"name":41,"class":42},"University of Louisville","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100596369","NCT07044557","MeDex: No Perioperative Dexamethasone in Brain Metastases","Inclusion Criteria:\n\n1. New brain tumor(s) on imaging\n2. Visceral mass(es) suspicious or confirmed for neoplasm\n\n   a. Patients with lung mass suspicious for primary lung cancer and no prior diagnosis must undergo biopsy of the lung mass prior to resection of brain metastasis(es) to exclude histology (i.e., small cell lung carcinoma) that would not benefit from resection\n3. No contraindications for craniotomy\n4. Age ≥ 18 years\n5. ECOG performance status ≤ 2 (i.e., ambulatory \\> 50% of waking hours)\n6. Midline shift on MRI ≤ 10 mm\n7. Craniotomy planned to resect \\>75% of the enhancing mass (surgeon's judgment)\n\nExclusion Criteria:\n\n1. Presence of BMs not eligible for resection that are each \\> 2 cm in any one dimension\n2. \\>4 BMs not eligible for resection that are each 2 cm in any one dimension\n3. Treatment with laser interstitial thermal therapy (LITT)\n4. High concern for primary CNS lymphoma\n5. Diagnosis of small cell lung carcinoma\n6. Any receipt of Dex\n7. Steroid use in the past month\n8. A condition that requires steroids\n9. Stage 4 chronic kidney disease (GFR\\\u003C30)\n10. Pregnant or breastfeeding",{"count":50,"type":21},35,"INTERVENTIONAL",[53],"NA","Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).",[56],"Brain Metastases","RECRUITING","2026-05-28",{"date":60,"type":35},"2026-05-29",{"date":62,"type":21},"2026-08-01",{"date":64,"type":21},"2027-10",{"name":41,"class":42},{"id":67,"slug":4,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":43},"100612236","NCT07250958","Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage","Dome-Only Aneurysm Coiling in Severe Aneurysmal Subarachnoid Hemorrhage Observational Study","DOME","Inclusion Criteria:\n\n* 18 years or older\n* CT confirmed aSAH with an angiographically detected aneurysm\n* World Federation of Neurological Sciences (WFNS) aSAH grade 3-5 aneurysm\n* LAR available and gives consent within 72 hours after the onset of aSAH (or last known normal\n\nExclusion Criteria:\n\n* Patients whose aneurysm judged appropriate for balloon-assisted coiling\n* Patients whose aneurysm is bleeding from the \"neck\"\n* Patients who are clinically judged to suffer imminent death within 24 hours.\n* Pregnancy or positive urine pregnancy test",{"count":74,"type":21},30,"The DOME study is a clinical trial exploring a new treatment approach for patients who suffered a severe brain bleed due to an aneurysm.",[77],"Aneurysmal Subarachnoid Hemorrhage","2026-05-05",{"date":80,"type":35},"2026-05-11",{"date":82,"type":35},"2026-03-12",{"date":84,"type":21},"2027-01",{"name":41,"class":42},{"id":87,"slug":4,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":51,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":43},"100471502","NCT05419713","Intermediate Visual Space Perception","Visual Mechanisms of Intermediate Distance Space Perception During Self-motion","Inclusion Criteria:\n\n* Adults (up to 40 years of age)\n* Children (18 years and older)\n* Normal, or corrected-to-normal, visual acuity (at least 20\u002F20)\n* Stereo acuity (\\\u003C20 arc sec).\n\nExclusion Criteria:\n\n* Self-reported history of visual and eye diseases\n* Physical movement restrictions.\n* Vulnerable populations such as pregnant women will be excluded owing to the extensive time commitment required of the subjects.","40 Years",{"count":94,"type":21},180,[53],"The ability to judge the locations of various objects from oneself during self-motion in the intermediate distance range (\\~2-25m) is crucial for successful performance of activities of daily living, such as walking and driving. However, little is known about the mechanisms of visual space perception involved in judging distance, the focus of this project, in the planning and\u002For execution of self-motion in the natural 3D environment. The theoretical knowledge to be gained from this project will contribute to the scientific literature and provide insights into how eye and neurological defects could impair visual space perception, wayfinding, and mobility.",[98],"Vision",{"date":100,"type":35},"2026-05-07",{"date":102,"type":35},"2021-09-30",{"date":32,"type":21},{"name":41,"class":42},{"id":106,"slug":4,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":111,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":51,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100596382","NCT07044726","Betadine vs Sterile Water for Periurethral Preparation","Betadine vs Sterile Water for Periurethral Preparation Prior to Straight Catherization in the Clinic Setting: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18+\n* Patient undergoing in office straight catherization\n\nExclusion Criteria:\n\n* History of culture proven recurrent urinary tract infection (2 in any 6-month period or 3 in any 12-month period)\n* Urine Analysis with +Nitrites\n* Catherization for any reason in the last 4 weeks\n* History of Iodine allergy\n* Patients unable to speak English\n* Patient does not have the capacity to consent\n* 2-3rd trimester pregnancy","FEMALE",{"count":113,"type":21},148,[115],"PHASE4","The purpose of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water (water that has been treated to remove bacteria and living organisms) vs Betadine also known as Povidone-Iodine (a medical grade cleaning solution) changes the rates of bacteria in the urine after a temporary catheter, or draining tube, is placed into the bladder. Chemical antiseptics, including Betadine, are the current standard of care. An additional goal of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water vs betadine changes the amount of discomfort or pain patients experience with placement of a temporary catheter, or draining tube, in the bladder.",[118,119],"Catherization","Urinary Tract Infection Bacterial",[121,122,118],"Betadine","Sterile Water","2026-05-01",{"date":125,"type":35},"2026-05-04",{"date":127,"type":35},"2025-06-30",{"date":129,"type":21},"2028-05-21",{"name":41,"class":42},2,{"id":133,"slug":4,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":51,"phases":140,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":43},"100635711","NCT07556237","Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis","HEAL","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed gastroparesis.\n* Implanted Enterra™ device for at least 8 weeks prior to enrollment.\n* Chronic daily abdominal pain of gastric origin lasting more than 2 months.\n* Average pain score ≥4 on a 0-10 scale.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Daily opioid use.\n* Pregnancy or breastfeeding.\n* Abdominal pain not attributed to gastric\u002Fvisceral origin.\n* Severe constipation or uncontrolled diabetes (HbA1c \\>10).\n* Other medical conditions that would interfere with study participation.",{"count":139,"type":21},150,[53],"Gastroparesis is a disorder characterized by delayed gastric emptying and symptoms including nausea, vomiting, and abdominal pain. Gastric electrical stimulation (GES) using the implanted Enterra™ neurostimulator is FDA-approved to treat nausea and vomiting but its impact on abdominal pain has not been well studied. This study evaluates whether alternative programming parameters of the Enterra™ device can reduce abdominal pain in patients with gastroparesis. Participants with an existing Enterra™ device will be randomized to one of three stimulation settings and followed for assessment of pain, gastrointestinal symptoms, quality of life, and medication use.",[143,144],"Gastroparesis","Chronic Abdominal Pain",[146,147,148,149,150],"Gastric Electrical Stimulation","Enterra","Visceral pain","Gastroparesis pain","Neuromodulation","2026-04-28",{"date":125,"type":35},{"date":154,"type":21},"2026-07",{"date":156,"type":21},"2030-07",{"name":41,"class":42},{"id":159,"slug":4,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100453109","NCT05180253","Esophageal and Gastric Registry and Biorepository","Healthy Control Esophageal and Gastric Registry and Biorepository","Inclusion Criteria:\n\n* Age 18-85\n* No prior surgical history\n* Asymptomatic according to gastroesophageal and gastric questionnaires\n* Not currently taking any medications that affect acid secretion or gut motility\n* No history of malignancy\n* No mental health issues precluding informed consent\n* No smoking history\n* No excessive or daily alcohol use\n* BMI \\\u003C 30\n* No known hiatus hernia\n* No known medical illness (autoimmune, neurological) that could be associated with altered esophageal or gastric function\n* Not allergic to fentanyl or versed\n* No history of eating disorder\n* No history of autoimmune disorders\n\nExclusion Criteria:\n\n* Minors\n* Surgeries involving the GI tract\n* Medication use affecting acid secretion or gut motility\n* Personal history of malignancy\n* Mental health issues precluding informed consent\n* Symptoms on standard clinical questionnaires\n* Pregnant - the effect that pregnancy has on esophageal and gastric motility is not well defined, but we will need to eliminate this as a confounding factor\n* Nursing women - although the investigations are FDA approved and part of standard clinic practices, they are time consuming and involve medication administration that might affect the ability of a mother to nurse","85 Years",{"count":5,"type":21},"The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract.\n\nWe will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.",[168],"Gastro Esophageal Reflux",[170,171],"Mucosal Integrity","Functional Luminal Imaging Probe",{"date":125,"type":35},{"date":174,"type":35},"2023-01-09",{"date":176,"type":21},"2026-06",{"name":41,"class":42},{"id":179,"slug":4,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":51,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":131},"100631697","NCT07504055","Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury","Effectiveness of Transcutaneous Spinal Cord Stimulation on Blood Pressure Regulation in Individuals With Chronic Spinal Cord Injury","Inclusion Criteria:\n\n* At least 18 years old,\n* Stable medical condition,\n* Non-progression SCI (no negative change in the neurological level and motor-completeness assess during screening when compared to the neurological status assessed at 6-month period after injury or at least 6 months prior to the screening),\n* Motor-complete SCI according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade \"A,\" \"B,\" or \"C\" above T1 spinal level according to the ASIA International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Neurological Level of Injury (NLI),\n* Sustained SCI at least 12 months prior to entering the study,\n* Evidence of symptomatic hypotension as determined by a total score \\>0 on the Orthostatic Hypotension Symptom Assessment (OSHA),\n* Normal renal function as defined by eGFR \\> 59 ml\u002Fmin\u002F1.73, creatinine value within the range of 0.6-1.2 mg\u002Fdl, and BUN values within the range of 7-18 mg\u002Fdl,\n* Competent to give informed consent for the research protocol,\n* Able to understand instructions.\n\nExclusion Criteria:\n\n* Major pulmonary or cardiovascular disease unrelated to SCI,\n* Ventilator dependence,\n* Painful musculoskeletal dysfunction that might interfere with testing or stimulation,\n* Unhealed fracture that might interfere with testing or stimulation,\n* Unhealed contracture that might interfere with testing or stimulation,\n* Unhealed pressure sore that might interfere with testing or stimulation,\n* Untreated clinically significant depression or psychiatric disorders,\n* Ongoing drug abuse,\n* Malignancy ,\n* Class III obesity (BMI \\>40) and at least one co-morbidity thereof: a) Type 2 diabetes as defined by ≥6.5% level on two separate glycated hemoglobin (A1C) tests, b) hypertension as defined by consistent blood pressure readings of ≥140\u002F90 mmHg or taking medication for blood pressure,\n* Acute or chronic obstructive deep vein thrombosis,\n* Secondary hypotension unrelated to SCI (anemia, hypervolemia, endocrine and neurological diseases),\n* Major esophageal\u002Fgastrointestinal problem,\n* Currently pregnant (females of childbearing potential only),\n* Other major medical illness contraindicated for testing or stimulation.",{"count":5,"type":21},[53],"The goal of this clinical trial is to learn if non-invasive spinal cord stimulation intervention improves blood pressure regulation in individuals with chronic spinal cord injury. The main questions it aims to answer are:\n\n* Can site specific spinal cord stimulation enhance blood pressure regulation?\n* Does this stimulation affect enzymes responsible for blood pressure regulation? Researchers will stimulate different sites of spinal cord and compare to see if site-specific stimulation provide blood pressure stability.\n\nParticipants will have up to six pairs of self-adhesive conductive electrodes placed on the skin over the spinal cord (midline and\u002For just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and\u002For abdominal muscles (left and right of the umbilicus) as anodes for stimulation of the spinal cord.",[188,189,190],"Spinal Cord Injury","Orthostatic Hypertension","Autonomic Dysreflexia","2026-04-27",{"date":151,"type":35},{"date":194,"type":35},"2026-04-01",{"date":196,"type":21},"2029-02",{"name":41,"class":42},{"id":199,"slug":4,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":43},"100353008","NCT03876288","Gastroparesis Outcome Longitudinal Database Enrolled Numerically","GOLDEN","Inclusion:\n\n* Patients with the symptoms (Sx) of drug refractory gastroparesis\n* Disordered nutrition by standardized assessment\n* Ability to assess current symptom status\n* Ability to measure other medical conditions\n\nExclusion:\n\n* Anatomic obstruction of the GI Tract\n* Pregnancy\n* Inability of patient or guardian to sign informed consent, if needed\n* Psychiatric disorders precluding assessment and treatment of the patient's GI condition",{"count":205,"type":21},3000,"GOLDEN is a longitudinal database of patients with the symptoms (Sx) of gastroparesis (Gp) who were seen and recorded at the University of Louisville from 2012 and is ongoing. Patients are enrolled and followed by sequential numbers and may include legacy patients seen at other centers by some of the same team and who are reported as part of the series. Outcome relate to patients Sx, survival, quality of life and other measures as detailed below, over time. The study tracks patients regardless of treatment but specifically focuses on GI Neuromodulation (gastric electrical stimulation - GES), Immunotherapy (IVIG), and Pyloric therapies (pyloroplasty, endoscopic). If treatments were administered GOLDEN allows for examination and stratification of outcome by groups both at baseline and at follow up.",[143],"2026-04-17",{"date":210,"type":35},"2026-04-20",{"date":212,"type":35},"2013-01-01",{"date":214,"type":21},"2028-01-01",{"name":41,"class":42},{"id":217,"slug":4,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":51,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":43},"100517623","NCT06019949","Spinal Cord Stimulation for Respiratory Rehabilitation in Patients With Chronic Spinal Cord Injury","Neuromodulatory Rehabilitation for Respiratory Motor Function in Individuals With Chronic Spinal Cord Injury","Inclusion Criteria:\n\n* At least 18 years old;\n* stable medical condition;\n* no painful musculoskeletal dysfunction, unhealed fracture, contracture, pressure sore or urinary tract infection that might interfere with respiratory training or stimulation;\n* no clinically significant depression, psychiatric disorders or ongoing drug abuse;\n* non-progressive SCI (no negative change in the neurological level and motor-completeness assessed during screening when compared to the neurological status assessed at 6-mo period after injury or at least 6 months prior to the screening), non-ventilator dependence, motor-complete SCI according to the American Spinal Injury Association Impairment Scale (AIS) grade \"A\" or \"B\" above T5 spinal level;\n* sustained SCI at least 12 months prior to entering the study;\n* compared to the normative values for healthy population, at least 15%-deficit in pulmonary function outcomes (FVC and FEV1) as detected by screening spirometry.\n\nExclusion Criteria:\n\nParticipants will be excluded from the study if there is a presence of\n\n* major pulmonary or cardiovascular disease,\n* ventilator dependence,\n* endocrine disorders,\n* malignancy,\n* marked obesity,\n* deep vein thrombosis,\n* HIV\u002FAIDS-related illness,\n* secondary hypotension (anemia, hypervolemia, endocrine and neurological diseases),\n* major esophageal\u002Fgastrointestinal problem or other major medical illness contraindicated for respiratory training or testing.\n\nDuring screening, the potential participant will be asked whether she is pregnant or planning to become pregnant during the study period. Pregnant women are excluded from this study, as the risk to the fetus is unknown. No pregnancy test or birth control regimen will be required.",{"count":223,"type":21},36,[53],"Respiratory complications are among the leading causes of death in patients with chronic spinal cord injury (SCI). Our previous work showed that pulmonary function can be improved by using our original respiratory training method. However, the effectiveness of this intervention is limited due to the disruption of brain-spinal connections and consequently lowered spinal cord activity below the injury level. Our recent studies showed that electrical stimulation of the spinal cord below the level of injury leads to increased ventilation which indicates activation of the spinal cord structures related to respiration. These findings indicate that spinal cord stimulation can be a promising therapeutic additive to the treatment. The goal of this study is to justify the establishment of a new direction in rehabilitation for patients with SCI by using a non-invasive spinal cord stimulation in combination with respiratory training.\n\nOur aims are: 1) to evaluate the effects of such stimulation applied to the injured spinal cord on pulmonary function and respiratory muscle activity, and 2) to evaluate the effectiveness and therapeutic mechanisms of the spinal cord stimulation combined with respiratory training. Thirty-six individuals with chronic SCI will be recruited and assigned to three groups to receive respiratory training or spinal cord stimulation alone or a combination of them. All participants will be tested before and after cycles of experimental procedures with\u002For without stimulation. Our hypotheses will be confirmed if the respiratory training combined with spinal cord stimulation results in the most enhanced positive effects.",[227,228],"Spinal Cord Injuries","Respiration Disorders",[188,230,231],"Respiration","Rehabilitation","2026-03-11",{"date":234,"type":35},"2026-03-13",{"date":236,"type":35},"2023-09-10",{"date":238,"type":21},"2030-04-10",{"name":41,"class":42},{"id":241,"slug":4,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":51,"phases":247,"briefSummary":248,"conditions":249,"keywords":252,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":43},"100452941","NCT05178056","Spinal Cord Stimulation and Respiration After Injury","Epidural Spinal Cord Stimulation and Respiratory Motor Function After Injury","Inclusion Criteria:\n\n* At least 18 years old\n* Stable medical condition\n* Non-progressive C3-T1 AIS A-C Spinal Cord Injury (SCI)\n* Sustained SCI at least 24 months prior to entering the study\n* At least 15%-deficit in pulmonary function outcomes\n\nExclusion Criteria:\n\n* Painful musculo-skeletal dysfunction\n* Unhealed fracture\n* Contracture\n* Pressure sore\n* Urinary tract infection that might interfere with respiratory training\n* Clinically significant depression\n* Psychiatric disorders\n* Ongoing drug abuse;\n* Major cardiovascular disease\n* Major pulmonary disease\n* Ventilator dependence\n* Major endocrine disorders\n* Malignancy\n* Marked obesity\n* Deep vein thrombosis\n* HIV\u002FAIDS related illness\n* Secondary causes of respiratory dysfunction\n* Major gastrointestinal problems\n* Other major medical illness contraindicated for respiratory training\n* Pregnantcy",{"count":74,"type":21},[53],"Respiratory motor control deficit is the leading cause of morbidity and mortality in patients with spinal cord injury. The long-term goal of this NIH-funded study is to develop a rehabilitation strategy for respiration in patients with spinal cord injury as a standard of care. Respiratory function in patients with chronic spinal cord injury can be improved by using inspiratory-expiratory pressure threshold respiratory training protocol. However, the effectiveness of this intervention is limited by the levels of functional capacity preserved below the neurological level of injury. Preliminary data obtained for this study demonstrate that electrical spinal cord stimulation applied epidurally at the lumbar level in combination with respiratory training can activate and re-organize spinal motor networks for respiration. This study is designed to investigate respiratory motor control-related responses to epidural spinal cord stimulation alone and in combination with respiratory training. By characterization of respiratory muscle activation patterns using surface electromyography in association with pulmonary functional and respiration-related cardiovascular measures, the investigators expect to determine the specific stimulation parameters needed to increase spinal excitability below level of injury to enhance responses to the input from supraspinal centers that remain after injury and to promote the neural plasticity driven by the respiratory training. This hypothesis will be tested by pursuing two Specific Aims: 1) Evaluate the acute effects of epidural spinal cord stimulation on respiratory functional and motor control properties; and 2) Evaluate the effectiveness of epidural spinal cord stimulation combined with respiratory training.",[227,250,251,231],"Spinal Cord Stimulation","Breathing Exercises",[253,254],"Epidural Spinal Cord Stimulation","Respiratory Training",{"date":234,"type":35},{"date":257,"type":35},"2021-12-31",{"date":259,"type":21},"2030-12-31",{"name":41,"class":42},{"id":262,"slug":4,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":51,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":43},"100577926","NCT06804642","Spinal Cord Stimulation for Parkinson's Disease Rehabilitation","Rehabilitation of Locomotor Function in Parkinson's Disease by Non-invasive Spinal Cord Stimulation","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease;\n* Adults aged 18 to 80 years;\n* Competent to give informed consent for the research protocol;\n* Able to understand instructions;\n* Able to ambulate 10-meters.\n\nExclusion Criteria:\n\n* Co-morbidities affecting gait;\n* Clinically significant cognitive dysfunction;\n* Clinically significant depression or major active psychiatric illness such as schizophrenia, bipolar disorder, or major depressive disorder;\n* Terminal illness associated with \\\u003C12-month survival;\n* Have a current diagnosis or condition such as major cardiac insufficiency, determined clinically by the study doctors;\n* Current alcohol or substance abuse that is uncontrolled or unmanageable;\n* Individuals unable to communicate with the investigator and study staff; and\u002For\n* Individuals with any illness that, in the study doctors' opinion, may preclude them from spinal cord transcutaneous stimulation, activity-based recovery training, or participation in study assessments.","80 Years",{"count":269,"type":21},20,[53],"This study explores the use of multifunctional, non-invasive spinal cord transcutaneous stimulation (scTS) to address axial motor symptoms, particularly gait dysfunction, in Parkinson's disease (PD). These symptoms, resistant to levodopa and inadequately managed by deep brain stimulation (DBS), arise from maladaptive spinal network changes. A non-invasive approach like scTS could overcome limitations associated with invasive spinal cord stimulation (SCS), which requires surgical implantation and lacks adaptability in stimulation site adjustments.\n\nGait dysfunction in PD stems from disrupted interactions between spinal and supraspinal networks. scTS provides a non-invasive alternative, shown to enhance locomotor functions in conditions such as spinal cord injury, stroke, and cerebral palsy. This study hypothesizes that scTS applied at multiple spinal levels-cervical (C3-C4), thoracic (T11-T12), and lumbar (L1, L2-L3)-can synergistically activate locomotor central pattern generators (CPGs) and improve gait and postural control in PD. Additionally, it is hypothesized that proprioceptive input, combined with scTS, can counteract disruptions in spinal networks and restore voluntary movement.\n\nThe primary goal is to evaluate the effects of scTS on stepping performance, postural control, and locomotor recovery in PD. Specific objectives include:\n\n1. Enhancing Locomotor Networks\n\n   * Determine optimal scTS parameters for inducing rhythmic stepping in PD patients.\n   * Assess interactions between spinal and supraspinal networks during imagined stepping under scTS in a gravity-neutral setting.\n2. Improving Postural Networks\n\n   o Evaluate the effectiveness of scTS in restoring postural control and integrating postural-locomotor functions.\n3. Facilitating Neuroplasticity for Movement Recovery o Combine scTS with activity-based recovery training to promote adaptive plasticity in spinal and cortical networks, reducing freezing of gait (FOG).\n\nThe research will measure scTS's capacity to generate coordinated stepping and postural movements, integrate proprioceptive feedback, and induce long-term improvements in gait parameters. By targeting spinal locomotor and postural systems, scTS offers a novel, non-invasive approach to addressing gaps in the management of PD gait dysfunction. This work has the potential to significantly enhance the quality of life for individuals with PD, providing a safe, adaptable, and patient-centered therapeutic solution.",[273],"Parkinson Disease",[275,276,277,278,279,280],"Parkinson disease","spinal cord","freezing gate","rehabilitation","non-invasive stimulation","neuromodulation","2026-03-09",{"date":232,"type":35},{"date":284,"type":35},"2024-12-12",{"date":286,"type":21},"2035-12-31",{"name":41,"class":42},{"id":289,"slug":4,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":136,"eligibilityCriteria":292,"healthyVolunteers":16,"sex":17,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":51,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":43},"100337213","NCT03670524","Health, Environment and Action in Louisville (HEAL) Green Heart Louisville Project","Inclusion Criteria:\n\n* 30-70 years of age.\n* Live within the targeted study location\n\nExclusion Criteria:\n\n* Unwilling or unable to provide consent.\n* HIV\u002FAIDS, active treatment for cancer, active bleeding including wounds.\n* Body weight less than 100 pounds or BMI\\>40.\n* Prisoners and other vulnerable populations.\n* Anyone that PI thinks is unsafe to participate in study.","30 Years","70 Years",{"count":296,"type":21},835,[53],"The purpose of this study is to examine how the environment and neighborhood characteristics affects the health of the area residents. The study will help determine how changing neighborhood characteristics, such as green space, affect heart health, risk factors for other diseases, sense of well- being or neighborhood cohesion.",[300,301],"Cardiovascular Diseases","Metabolic Health","2026-02-06",{"date":304,"type":35},"2026-02-10",{"date":306,"type":35},"2018-05-03",{"date":308,"type":21},"2028-10-30",{"name":41,"class":42},{"id":311,"slug":4,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":316,"targetDuration":4,"studyType":51,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100570303","NCT06705491","Trauma-Informed Procedural Pain Intervention: Refinement of an Evidence-Based Protocol","TIPPI-R","Inclusion Criteria:\n\n* Patient is receiving treatment at Norton Children's Cancer Institute, Norton Children's Hospital, University of Kentucky Children's Hospital or DanceBlue Clinic.\n* Patient has been diagnosed with an oncology diagnosis.\n* Patient and family are English-speaking.\n* Patient is between the ages 0-18.\n\nExclusion Criteria:\n\n* Families not proficient in English.\n* Patient is 19 years or older.\n* Patient is not receiving treatment at Norton Children's Cancer Institute, Norton Children's Hospital, University of Kentucky Children's Hospital or DanceBlue Clinic.\n* Patient does not have an oncology diagnosis.\n* Patient and family have any CPS involvement.",{"count":317,"type":21},100,[53],"The Trauma-Informed Procedural Pain Intervention (TIPPI-R) has been developed as a standardized way to provide education and teach evidence-based strategies for managing pain and distress that may occur during pediatric cancer treatment. The purpose of this clinical trial study is to test how helpful TIPPI-R is in supporting children and families manage pain and distress during the initial stages of cancer treatment. The main questions this study aims to answer are:\n\n* Does TIPPI-R increase use of helpful pain coping strategies for pediatric cancer patients?\n* Does TIPPI-R help lower perceived pain intensity during initial stages of cancer treatment?\n* Does TIPPI-R increase patient and family confidence in coping with pain and distress during cancer treatment?\n\nResearchers will compare pain experiences and use of pain coping strategies for families who receive the TIPPI-R intervention and families who receive standard of care to see if TIPPI-R decrease pain and distress during the initial stages of cancer treatment.\n\nParticipants will:\n\n* Complete surveys to measure pain and distress within 5 weeks of initial diagnosis (Time 1)\n* Either receive the TIPPI-R intervention or standard of care\n* Complete surveys to measure pain and distress 4 weeks after initial consent or TIPPI-R intervention delivery (Time 2)",[321,322],"Procedural Pain","Cancer-related Pain","2026-01-28",{"date":325,"type":35},"2026-01-30",{"date":327,"type":35},"2025-02-07",{"date":329,"type":21},"2026-12",{"name":41,"class":42},4,{"id":333,"slug":4,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":17,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":51,"phases":343,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":43},"100452942","NCT05178069","LGG Supplementation in Patients With AUD and ALD","Lactobacillus Rhamnosus GG: A Novel Probiotic Therapy for Treating Alcohol Use Disorder","AUD+ALD","Inclusion Criteria:\n\n1. Breath alcohol concentration (BAC) equal to 0.00 when the participant signs the informed consent document.\n2. Age between 21 and 65 years old (inclusive).\n3. Willingness to receive trial treatment.\n4. Ability to provide informed consent\n5. Understanding that this is not an alcohol treatment study.\n6. Heavy drinking. Men must consume ≥ 20 and women ≥ 14 standardized alcoholic beverages a week for the past 3 months.\n7. Diagnosis of Alcohol Use Disorder using DSM V criteria.\n8. 50 \\\u003CAST\\\u003C400 U\u002FL; AST \\> ALT; and ALT \\\u003C 200 U\u002FL; total bilirubin \\> 1.2 mg\u002FdL\n9. Model for End-Stage Liver Disease: 8 ≤ (MELD) ≤19.\n10. Good health as confirmed by medical history, physical examination, ECG, laboratory tests and vital signs except for liver injury and AUD related history.\n11. Provide contact information for someone who may be able to contact the subject in case of a missed appointment.\n12. . Females of child-bearing potential must not be pregnant and must be using birth control\n\nExclusion Criteria:\n\n1. Current (last 12 months) DSM V diagnosis of dependence on any psychoactive substance other than alcohol or nicotine,\n2. Positive urine drug screen at baseline for any illegal substance other than marijuana,\n3. History of hospitalization for alcohol intoxication delirium, alcohol withdrawal delirium or seizure,\n4. Participation in any research study for alcoholism treatment within 3 months prior to signing the informed consent,\n5. Pharmacological treatment with naltrexone, acamprosate, topiramate, or disulfiram within 1 month prior to randomization,\n6. Lifetime diagnosis based on DSM-V criteria of schizophrenia, bipolar disorder, or other psychosis, eating disorders; current or past year diagnosis of major depression\n7. In the investigators' opinion, moderate to severe risk of suicide (e.g., active plan, or recent attempt in last 6 months),\n8. Current use of psychotropic medications that cannot be discontinued,\n9. Clinically significant medical abnormalities (apart from moderate ALD, MELD≤19),\n10. Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) \\>10, at screening for more than 3 days,\n11. Serious medical diseases, such as cancer, liver cirrhosis, pancreatitis, severe alcohol associated hepatitis, heart chronic failure, chronic kidney failure, chronic intestinal diseases (e.g., Crohn's disease), chronic neurological disorders (e.g., tardive dyskinesia, epilepsy, Parkinson's disease)\n12. History of clinically significant hypotension (e.g., history of lipotimia and\u002For syncopal episodes)\n13. History of adverse reactions to needle puncture,\n14. Obesity (BMI ≥ 33.0 kg\u002Fm2),\n15. Pregnancy; incarceration; inability to provide consent\n16. Signs of systemic infection: Fever \\> 38o C, positive blood or ascites cultures, on appropriate antibiotic therapy for \\> 3 days within 3 days of inclusion\n17. Acute gastrointestinal bleeding requiring \\> 2 units blood transfusion within the previous 2 weeks\n18. Undue risk from immunosuppression: Positive HBsAg; positive skin PPD skin test or history of treatment for tuberculosis; known HIV infection","21 Years","65 Years",{"count":342,"type":21},60,[344],"PHASE2","To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH",[25,26],[348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363],"AUD","ALD","AH","TLFB","LTDH","AUDIT","WHO Drinking Level Reduction Criteria","MELD","ALT","AST","ABIC","Total Bilirubin","Heavy Drinking","Drinking Pattern","AUD Domains","Albumin","2025-10-29",{"date":366,"type":35},"2025-10-31",{"date":368,"type":35},"2022-06-01",{"date":370,"type":21},"2027-02-28",{"name":41,"class":42},{"id":373,"slug":4,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":51,"phases":379,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":43},"100322927","NCT03484299","Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* greater than or equal to 18 years of age\n* diagnosed with stage III pancreatic cancer\n* tumor is measurable\n* GFR \\> mL\u002Fmin\u002F1.73m2\n* willing and able to comply with protocol requirements\n* AST\u002FALT \\>3 times upper limit of normal\n* stable surgical post-operative course as defined by operative surgeon\n\nExclusion Criteria:\n\n* participating in another clinical trial for the treatment of cancer at the time of screening\n* pregnant or currently breast feeding\n* have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure\n* have non-removable implants with metal parts within 1 cm of the target lesion\n* had a myocardial infarction within 3 months prior to enrollment",{"count":269,"type":21},[380],"PHASE1","Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.",[383],"Pancreas Cancer","2025-10-27",{"date":364,"type":35},{"date":387,"type":35},"2018-05-30",{"date":389,"type":21},"2027-07-31",{"name":41,"class":42},{"id":392,"slug":4,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":51,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":43},"100291989","NCT03080974","Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* ≥ 18 years if age\n* Diagnosed with stage III pancreatic cancer\n* Tumor is measurable\n* Glomerular Filtration Rate \\> 60 m\u002FL\u002Fmin\u002F1.73 m(2)\n* Willing and able to comply with the protocol requirements\n* Able to comprehend and have signed the informed consent to participate\n\nExclusion Criteria:\n\n* Participating in another clinical trial for the treatment of cancer at time of screening\n* Are pregnant or currently breast feeding\n* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure\n* Have non-removable implants with metal parts within 1 cm of the target lesion\n* Had a myocardial infarction within 3 months prior to enrollment",{"count":397,"type":21},10,[344],"Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.",[401],"Pancreatic Adenocarcinoma",[403,404],"irreversible electroporation","Nivolumab",{"date":364,"type":35},{"date":407,"type":35},"2017-08-14",{"date":409,"type":21},"2029-04-01",{"name":41,"class":42},{"id":412,"slug":4,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":340,"enrollmentInfo":418,"targetDuration":4,"studyType":51,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":43},"100532115","NCT06208605","Innovations in Personalizing Treatment Study","Innovations in Personalizing Treatment for Eating Disorders Using Idiographic Methods and the Impact of Personalization on Psychological, Physical, and Sociodemographic Outcomes","T-NIPT-ED","Inclusion Criteria:\n\n* Current diagnosis of any active eating disorder except ARFID\n* Ages 18-65\n\nExclusion Criteria:\n\n* Active Suicidality\n* Active Mania\n* Active psychosis",{"count":419,"type":21},320,[53],"Eating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDOH). Treatment response for EDs are suboptimal; there are no evidence-based treatment for adults with anorexia nervosa (AN) or Other Specified Feeding or Eating Disorder (OSFED) and only 50% of adults respond to current evidence based treatments. There are no precision treatments, nor any treatments that consider social context, in existence. Personalized treatments for EDs, that consider social contexts, are urgently needed to improve treatment response and minimize the suffering associated with these illnesses. The investigators' overall goal, extending upon their past work, is to create a treatment personalized based on idiographic (or one person) models (termed Transdiagnostic Network Informed Personalized Treatment for EDs; T-NIPT-ED). The investigators will carry out a two-phase study to systematically characterize individual mechanisms of treatment (Phase I: N=900) and then test the efficacy of each treatment module (Phase II: N=240 drawn from Phase I) compared to the current gold-standard treatment (Cognitive Behavioral Therapy Enhanced: CBT-E). The study goals are to (1) characterize the prevalence of T-NIPT-ED precision treatment mechanisms and medical and psychological comorbidities (e.g., obesity; depression), individual disease burden (e.g., disability), SDOH (e.g., food insecurity), and public health outcomes (e.g., service utilization) specific to these mechanisms, (2) identify if personalized target mechanisms improve when matched to evidence-based treatment modules of T-NIPT-ED and (3) test if change in T-NIPT-ED is associated with improved outcomes (vs CBT-E), including ED outcomes, comorbidities, disease burden, and public health outcomes and if these outcomes are moderated by SDOH. These goals will ultimately lead to the very first precision treatment for ED and can be extended to additional psychiatric illnesses. The proposed research uses highly innovative methods; intensive longitudinal data collected with mobile technology is combined with state-of-the art idiographic modeling methods to deliver a virtual, personalized treatment. This proposal integrates assessment of broad (e.g., SDOH; public health burden) and specific (e.g., ED symptoms) outcomes, to ensure that social context can be integrated into personalization. The proposed research has high clinical impact. Ultimately, this proposal will lead directly to the creation and dissemination of an evidence-based individually-personalized treatment for EDs, as well as will serve as an exemplar for precision treatment development across the entire field of psychiatry.",[423],"Eating Disorders",[425,426,427,428,429,430,431,432],"Eating disorder","Treatment","Public Health","anorexia nervosa","bulimia nervosa","binge eating disorder","Other specified feeding and eating disorder","atypical anorexia nervosa","2025-10-06",{"date":435,"type":35},"2025-10-08",{"date":437,"type":35},"2024-01-21",{"date":196,"type":21},{"name":41,"class":42},{"id":441,"slug":4,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":51,"phases":449,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":43},"100589381","NCT06953674","Saline Versus Balanced Crystalloid in Traumatic Brain Injury","Saline vs. Balanced Crystalloid in Traumatic Brain Injury","FLUID-TBI","Inclusion Criteria:\n\n* Trauma patients presenting to the Emergency Room for initial care\n* Glasgow Coma Scale ≤ 12\n* Head CT with skull fracture(s) and\u002For hemorrhage(s) (\\>1cm in any single dimension) with a reported mechanism of trauma\n\nExclusion Criteria:\n\n* Severe visceral trauma dictating mortality (visceral injury severity score \\> brain injury severity score)\n* Non-survivable brain injury based on the treating physician's judgment\n* Emergent visceral operative intervention before complete trauma assessment\n* Concern for ruptured intracranial vascular malformation\n* Patients who are transferred from another facility",{"count":448,"type":21},600,[450],"PHASE3","The goal of this clinical trial is to determine which crystalloid (saline or balanced) should be used in the critical management of Traumatic Brain Injury (TBI) in moderate or severe TBI patients. This trial will determine whether the use of saline or balanced crystalloids is associated with improved outcomes in TBI patients.\n\nParticipants will\n\n1. be given fluids through the veins, either saline or balanced fluid will be given.\n2. From the first day to the day 14 of the hospitalization (or discharge, whichever comes first), vital signs, laboratory values, treatments given, and other medical data will be collected from the medical record.\n3. Six months later, your final disability, if any, will be assessed during your follow-up with a doctor. It involves answering a short survey that will take about 5 minutes or less.",[453],"Traumatic Brain Injury (TBI) Patients","2025-08-12",{"date":456,"type":35},"2025-08-17",{"date":458,"type":35},"2025-06-01",{"date":460,"type":21},"2029-09",{"name":41,"class":42},{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":17,"minAge":468,"maxAge":469,"enrollmentInfo":470,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":43},"100378536","NCT04208828","IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy","GAIN","Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.\n\n\\-\n\nExclusion Criteria: Inability to receive intravenous immunoglobulin.\n\n\\-","12 Years","90 Years",{"count":471,"type":21},400,"Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions\u002F Some of these patients have serologic and\u002For endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.",[474,143,475],"Gastrointestinal Motility Disorder","Neuropathy",[143,477,478,479,475],"Nausea","Vomiting","Abdominal Pain","2025-07-29",{"date":482,"type":35},"2025-08-01",{"date":484,"type":35},"2020-01-02",{"date":486,"type":21},"2028-01-02",{"name":41,"class":42},{"id":489,"slug":4,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":51,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":43},"100594246","NCT07016945","Reactions to Distress (RED) In Louisville, KY Study","Reactions to Experiencing Distress (RED) Study","RED","Inclusion Criteria:\n\n* Eligibility for this study will include a positive response to the following questions: 1) Do you identify as Black or African American? 2) Have you ever in your lifetime personally experienced or witnessed another person experience any acts of racism or racial microaggressions? 3) Are you willing to complete a 1.5-hour study at the University of Louisville in the next 2 weeks? 4) Are you 18 or older?\n\nExclusion Criteria:\n\n* None",{"count":496,"type":21},270,[53],"The goal of this study is to understand whether race-related stress can impact the way people direct their attention and what interventions may be helpful for attention.",[500],"Threat Sensitivity",[502,503,504],"attention bias","mindfulness","stress","2025-06-09",{"date":507,"type":35},"2025-06-12",{"date":509,"type":35},"2024-07-25",{"date":511,"type":21},"2027-04-30",{"name":41,"class":42},{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":519,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":521,"conditions":522,"keywords":526,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":536,"locationsCount":43},"100555416","NCT06511804","Correlation Between Noninvasive Blood Vessel Functionality Parameters and Cerebral Hemodynamics in Neurocritical Care Patients","Mespere ICP","Inclusion Criteria:\n\nSubjects who meet all the following inclusion criteria may be included:\n\n1. Adults (\\> 18 years of age);\n2. Able and willing to provide written informed consent for participation by self or legally authorized representatives.\n3. Clinical diagnosis of traumatic brain injury (TBI), brain hemorrhage, brain tumor, neurotrauma (including closed head injuries, penetrating head injuries, or other forms of neurotrauma), hemorrhage (intracerebral or subarachnoid), or stroke.\n4. Continuous Blood Pressure Monitoring: Patients must have continuous blood pressure monitoring in place during the study period, obtained from an arterial line. This criterion ensures that we have real-time data on mean arterial pressure (MAP) and systolic pressure (SBP).\n5. Intracranial Pressure (ICP) Monitoring: Patients must have intracranial pressure (ICP) monitoring in place during the study period. This criterion ensures that we can assess the correlation between our blood vessel functionality parameters (VDC, VR, and VRx) and ICP, a key indicator of intracranial dynamics.\n\nExclusion Criteria:\n\n1. Subjects who meet any of the following exclusion criteria will be excluded:\n2. Expected to be at increased risk due to study participation (e.g. due to hemodynamic instability), in the medical opinion of an investigator;\n3. Pregnant as determined per site standard practice;\n4. Previously participated in this study, or are enrolled in another research study that could be expected to interfere with participation, in the opinion of the investigator;\n5. Require or are anticipated to require emergent medical care in which study participation may reasonably delay his\u002Fher medical care or increase risk or unfavorable outcome, in the opinion of the investigator;\n6. Allergy to adhesive tape;\n7. Ongoing photodynamic therapy.","100 Years",{"count":7,"type":21},"The purpose of this clinical research project is to employ Mespere LifeSciences NeurOs Cerebral Oximetry system, equipped with noninvasive sensors approved by the FDA, to monitor and investigate the correlation within a cohort of patients suffering from traumatic brain injury (TBI), stroke, brain tumor, and brain bleeding. This study aims to investigate and establish the correlation between blood vessel functionality parameters-specifically, Vasodilation\u002FConstriction Index (VDC), Vascular Resistance Index (VR), and Volume Reactivity Index (VRx)-with the crucial physiological indicators, Intracranial Pressure (ICP) and Mean Arterial Pressure (MAP). By doing so, the investigators seek to address fundamental questions surrounding cerebral hemodynamics and autoregulation in various neurological conditions.",[523,524,525],"Brain Injuries","Intracranial Pressure Increase","Monitoring",[527,528,529],"intracranial pressure","monitoring","noninvasive","2025-05-26",{"date":532,"type":35},"2025-05-30",{"date":534,"type":35},"2024-11-17",{"date":32,"type":21},{"name":41,"class":42},{"id":538,"slug":4,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":16,"sex":543,"minAge":544,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":51,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":43},"100537332","NCT06276452","Supporting Resilience Among Re-entered Seniors","SRRS","Inclusion Criteria:\n\n* at least 45 years old\n* have re-entered the community from a period of incarceration from jail or prison\n* have at least one chronic health condition\n* able to speak and understand English\n\nExclusion Criteria:\n\n* aged 44 or younger\n* have not re-entered the community from a period of incarceration from jail or prison\n* does not have at least one chronic health condition\n* unable to speak and understand English","MALE","45 Years",{"count":546,"type":21},8,[53],"The first goal (Aim 1) of this clinical trial is to learn about specific strengths, challenges, and desired areas of knowledge and skill-building among older adults who re-entered their communities from a period of incarceration and to then develop a new psychoeducational intervention tailored to these older adults. The second goal (Aim 2) of this clinical trial is to test if the intervention increases chronic disease management and whether the intervention is considered appropriate and acceptable by older adults who re-entered their communities from a period of incarceration.\n\nAim 1 participants will:\n\n* complete a baseline survey\n* participate in a focus group\n\nAim 2 participants will:\n\n* complete a baseline survey\n* participate in an 8-week once weekly intervention\n* complete three follow up surveys",[550],"Chronic Disease","2025-03-25",{"date":553,"type":35},"2025-03-26",{"date":555,"type":35},"2024-03-09",{"date":557,"type":21},"2026-11-30",{"name":41,"class":42},{"id":560,"slug":4,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":51,"phases":566,"briefSummary":567,"conditions":568,"keywords":572,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":43},"100583990","NCT06883513","Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID","Osteopathic Manipulative Therapy(OMT) Effects on Post-Acute Sequalae of COVID-19(PASC)","Inclusion Criteria:\n\n* \\- Individuals must claim they have had a prior positive SARS-CoV-2 test at least 6-weeks before the consenting process to proceed with the study\n* Individuals must claim they have at least one of the following symptoms greater than 6-weeks post infection that is affecting their daily life(these symptoms correlate with the SBQ™-LC):\n\nSymptoms of Long Covid Inclusion Criteria:\n\n* Shortness of breath or Difficulty Breathing\n* Difficulty with Movement (balance or tremor)\n* Muscle Pain or stiffness\n* Changes in sexual desire\n* Worsening Generalized Pain\n* Difficulty with Sleep\n* Changes in Mood (anxiety or depression)\n* Changes in Erectile function (Biological males only)\n* Palpations (irregular heart beats)\n* Altered Taste\n* Changes in your Hair\n* Changes in urination\n* Dizziness\n* Altered Smell\n* Changes in Skin\n* Changes in bowels\n* Fatigue\n* Indigestion\n* Dry or irritated eyes\n* Changes in sweating\n* Difficulty with Cognition (memory or thinking)\n* Stomach Pain\n* Changes in menstruation (Biological females only)\n* Chills or shivering\n\nExclusion Criteria:\n\n* If anyone denies they have any of the above symptoms before consent, they will be excluded from the trial\n\n  * They will also be excluded from the trial if they have suffered any fractured bones in the last 3 months (this will further decrease risk to the patient as the patient will be moved by the physician during the treatment protocol)\n  * Participants who are enrolled in other Long-COVID trials that have an intervention during their participation in this trial will be excluded. However, if they have a history of enrollment in a long-covid trial that has no interventions during this trial, they will not be excluded based on their history of acquiring experimental treatment.",{"count":269,"type":21},[53],"This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021.\n\nThe questions this study is trying to answer are:\n\n1. Does this OMT protocol improve other non-smell related Long-COVID symptoms\n2. Do 2 OMT treatments improve Long-COVID symptoms more than 1 OMT treatment\n\nParticipants will:\n\n1. Week 1: Take an digital survey regarding their Long-COVID symptoms undergo Long-COVID OMT treatment or a placebo treatment\n2. Week 2: Take an digital survey regarding their Long-COVID symptoms then all will undergo Long-COVID OMT treatment\n3. Week 3: Take an digital survey regarding their Long-COVID symptoms\n4. Week 8: Take an digital survey regarding their Long-COVID symptoms",[569,570,571],"Long-COVID","PASC","Long COVID Syndrome",[569,570],"2025-03-17",{"date":575,"type":35},"2025-03-19",{"date":577,"type":21},"2025-05-01",{"date":579,"type":21},"2025-07-03",{"name":41,"class":42},{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":589,"studyType":22,"phases":4,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":601},"100260791","NCT02674100","American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry","AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer","Inclusion Criteria:\n\n* Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.\n\nExclusion Criteria:\n\n* Have a cardiac pacemaker or ICD implant\n* Non-removable implants with metal parts near target lesion\n* Myocardial infarction within 3 months prior to enrollment\n* Not suitable for general endotracheal anesthesia",{"count":588,"type":21},500,"2 Years","The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.\n\nThe investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.",[592],"Pancreatic Cancer","2025-02-23",{"date":595,"type":35},"2025-02-25",{"date":597,"type":4},"2016-01",{"date":599,"type":21},"2030-01",{"name":41,"class":42},16,""]